参考文献/References:
[1] Organization WH. World Health statistics 2023:monitoring health for the SDGs,sustainable development goals[M]. 2023.
[2] 王添乐,杨晓,王剑. 蛋白质稳态在病理性心脏重塑中的作用[J]. 中华心血管病杂志,2021,49(7):719-723.
[3] Claugue MJ,URBé S,Komander D. Breaking the chains:deubiquitylating enzyme specificity begets function[J]. Nat Rev Mol Cell Biol,2019,20(6):338-352.
[4] Mooney EC,Sahingur SE. The Ubiquitin System and A20:implications in Health and Disease[J]. J Dent Res,2021,100(1):10-20.
[5] 邓青芳,马风伟. 去泛素化酶及其与人类疾病相关性的研究进展[J]. 贵州师范大学学报(自然科学版),2021,39(04):112-120.
[6] Zhan X,Yang Y,Li Q,et al. The role of deubiquitinases in cardiac disease[J]. Expert Rev Mol Med,2024,26:e3.
[7] Komander D,Rape M. The ubiquitin code[J]. Annu Rev Biochem,2012,81:203-229.
[8] Nijman SM,Luna-Vargas MP,Velds A,et al. A genomic and functional inventory of deubiquitinating enzymes[J]. Cell,2005,123(5):773-786.
[9] Shen K,Zhang Q. Literature review:nuclear factor kappa B (NF-κB) regulation in human cancers mediated by ubiquitin-specific proteases (USPs)[J]. Ann Transl Med,2024,12(5):90.
[10] Damgaard RB. The ubiquitin system:from cell signalling to disease biology and new therapeutic opportunities[J]. Cell Death Differ,2021,28(2):423-426.
[11] Xu J,Liang S,Wang Q,et al. JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKⅡδ in cardiomyocytes[J]. Cell Mol Life Sci,2024,81(1):18.
[12] Wang M,Han X,Yu T,et al. OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes[J]. Theranostics,2023,13(7):2263-2280.
[13] Yuan S,Wang Z,Yao S,et al. Knocking out USP7 attenuates cardiac fibrosis and endothelial-to-mesenchymal transition by destabilizing SMAD3 in mice with heart failure with preserved ejection fraction[J]. Theranostics,2024,14(15):5793-5808.
[14] Mevissen TET,Komander D. Mechanisms of deubiquitinase specificity and regulation[J]. Annu Rev Biochem,2017,86:159-192.
[15] Guo Q,Jin Y,Chen X,et al. NF-κB in biology and targeted therapy:new insights and translational implications[J]. Signal Transduct Target Ther,2024,9(1):53.
[16] Gong Y,Yu T,Shuai W,et al. USP38 exacerbates atrial inflammation,fibrosis,and susceptibility to atrial fibrillation after myocardial infarction in mice[J]. Mol Med,2023,29(1):157.
[17] Luo Y,Li WX,Zheng QS,et al. OTUD1 deficiency attenuates myocardial ischemia/reperfusion induced cardiomyocyte apoptosis by regulating RACK1 phosphorylation[J]. Acta Pharmacol Sin,2025,46(10):2649-2662.
[18] Xiao N,Li H,Luo J,et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFα-induced cancer cell migration[J]. Biochem J,2012,441(3):979-986.
[19] Fan YH,Yu Y,Mao RF,et al. USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation[J]. Cell Death Differ,2011,18(10):1547-1560.
[20] Niu J,Shi Y,Xue J,et al. USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO[J]. Embo j,2013,32(24):3206-3219.
[21] Ghiasi M. Investigating the NF-κB signaling pathway in heart failure:Exploring potential therapeutic approaches[J]. Heliyon,2024,10(23):e40812.
[22] Regamey A,Hohl D,Liu JW,et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor[J]. J Exp Med,2003,198(12):1959-1964.
[23] Yang XD,Li W,Zhang S,et al. PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome[J]. Embo j,2020,39(2):e102201.
[24] Wang Y ,Li Y ,Zhang W ,et al. NLRP3 Inflammasome:a novel insight into heart failure[J]. J Cardiovasc Transl Res,2023,16(1):166-176.
[25] Yalcinkaya M ,Liu W ,Thomas LA ,et al. BRCC3-Mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in tet2 clonal hematopoiesis[J]. Circulation,2023,148(22):1764-1777.
[26] Huang Z ,Shen S ,Wang M ,et al. Mouse endothelial OTUD1 promotes angiotensin Ⅱ-induced vascular remodeling by deubiquitinating SMAD3[J]. EMBO Rep,2023,24(3):e56135.
[27] Zhao Y ,Thornton AM ,Kinney MC ,et al. The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells[J]. J Biol Chem,2011,286(47):40520-40530.
[28] Kit L eng L ui S ,Iyengar PV ,Jaynes P ,et al. USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7[J]. EMBO Rep,2020,21(1):e49618.
[29] Bhattacharyya S ,Wang W ,Graham LV ,et al. A20 suppresses canonical Smad-dependent fibroblast activation:novel function for an endogenous inflammatory modulator[J]. Arthritis Res Ther,2016,18(1):216.
[30] Liu Y ,Li M ,Chen Z ,et al. BRISC-Mediated PPM1B-K63 deubiquitination and subsequent TGF-β pathway activation promote high-fat/high-sucrose diet-induced arterial stiffness[J]. Circ Res,2025,136(3):297-314.
[31] He B ,Zhao YC ,Gao LC ,et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of pathological cardiac hypertrophy[J]. Hypertension,2016,67(6):1237-1248.
[32] Ying X ,Zhao Y ,Yao T ,et al. Novel protective role for ubiquitin-specific protease 18 in pathological cardiac remodeling[J]. Hypertension,2016,68(5):1160-1170.
[33] Liu RP ,Mcmullen JR. Emerging role of targeting deubiquitinating enzymes to inhibit pathological cardiac hypertrophy [J]. J Am Heart Assoc,2025,14(6):e039732.
[34] Han J ,Fang Z ,Han B ,et al. Deubiquitinase JOSD2 improves calcium handling and attenuates cardiac hypertrophy and dysfunction by stabilizing SERCA2a in cardiomyocytes[J]. Nat Cardiovasc Res,2023,2(8):764-777.
[35] Shi X ,Xu J ,Liu L ,et al. Deubiquitinase MYSM1 drives myocardial ischemia/reperfusion injury by stabilizing STAT1 in cardiomyocytes[J]. Theranostics,2025,15(5):1606-1621.
[36] Yu ST ,Sun ZY ,Li N ,et al. Mettl1 knockdown alleviates cardiac I/R injury in mice by inactivating the Mettl1-CYLD-P53 positive feedback loop[J]. Acta Pharmacol Sin,2025,46(3):592-605.
[37] Marin-rubio JL ,Raote I ,Inns J ,et al. CYLD in health and disease[J]. Dis Model Mech,2023,16(6):dmm050093.
[38] Lork M ,Verhelst K ,Beyaert R. CYLD ,A20 and OTULIN deubiquitinases in NF-κB signaling and cell death:so similar,yet so different[J]. Cell Death Differ,2017,24(7):1172-1183.
[39] Bai W ,Huo S ,Li J ,et al. Advances in the study of the ubiquitin-editing enzyme A20[J]. Front Pharmacol,2022,13:845262.
[40] Zhang Y ,Zhu Z ,Cao Y ,et al. Rnd3 suppresses endothelial cell pyroptosis in atherosclerosis through regulation of ubiquitination of TRAF6[J]. Clin Transl Med,2023,13(9):e1406.
[41] Wang B ,Tang X ,Yao L ,et al. Disruption of USP9X in macrophages promotes foam cell formation and atherosclerosis[J]. J Clin Invest,2022,132(10):e154217.
[42] Chen Z ,Zhang SL. Endoplasmic reticulum stress :a key regulator of cardiovascular disease[J]. DNA Cell Biol,2023,42(6):322-335.
[43] 郭冰冰,金介员,项荣. 胸主动脉夹层遗传致病因素的研究进展[J]. 生命科学,2021,33(1):44-52.
[44] Li S ,Xiao X ,Chang Y ,et al. Berberine inhibits abdominal aortic aneurysm formation and vascular smooth muscle cell phenotypic switching by regulating the Nrf2 pathway[J]. J Cell Mol Med,2025,29(7):e70509.
[45] Fei X ,Song C ,Cui J ,et al. The role of deubiquitinases in cardiovascular diseases:mechanisms and therapeutic implications[J]. Front Cardiovasc Med,2025,12:1582049.
[46] Xian Y ,Ye J ,Tang Y ,et al. Deubiquitinases as novel therapeutic targets for diseases[J]. MedComm (2020),2024,5(12):e70036.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(12):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(12):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(12):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]